UnknownPHASE1, PHASE2NCT04138381
Selinexor as Single Agent and With Imatinib in Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (SeliGIST)
Studying Gastrointestinal stromal tumor
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Grupo Espanol de Investigacion en Sarcomas
- Principal Investigator
- Cesar Serrano, MDHospital Vall d´Hebron
- Intervention
- Selinexor(drug)
- Enrollment
- 30 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2019 – 2023
Study locations (6)
- Hospital Virgen del Rocio, Seville, Andalusia, Spain
- Hospital Universitario de Canarias, Santa Cruz de Tenerife, Canary Islands, Spain
- H Vall d'Hebrón, Barcelona, Catalonia, Spain
- Hospital Miguel Servet, Zaragoza, Zaragoza, Aragón, Spain
- Hospital La Paz, Madrid, Spain
- Hospital Virgen de la Arrixaca, Murcia, Spain
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04138381 on ClinicalTrials.govOther trials for Gastrointestinal stromal tumor
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07434843PH 2 Pemigatinib in SDH-deficient GISTDana-Farber Cancer Institute
- RECRUITINGPHASE1NCT07171203Neoadjuvant Imatinib and Fampridine in KIT Mutant Gastrointestinal Stromal TumorUniversity of California, San Diego
- RECRUITINGPHASE2NCT07406633KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line SettingKumquat Biosciences Inc.
- ENROLLING BY INVITATIONPHASE2NCT07550582Mesenteric Vascular Preconditioning Combined With Laparoscopic and Endoscopic Cooperative Surgery for Submucosal Tumor at the Gastroesophageal JunctionPeking University People's Hospital
- RECRUITINGNANCT07405125Safety of Robotic Surgery for GISTs at Special Anatomic SitesThe First Affiliated Hospital with Nanjing Medical University
- RECRUITINGPHASE3NCT07218926A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib TherapyGlaxoSmithKline
- RECRUITINGPHASE1, PHASE2NCT07096609Lenvatinib After Progression on Imatinib, Sunitinib, and Regorafenib for GIST PatientsAsan Medical Center
- RECRUITINGPHASE2NCT07559864Comparing Regorafenib Combined With Envafolimab to Physician's Choice in Patients With Metastatic Gastrointestinal Stromal Tumors Harboring KIT Exon 17 Mutations Refractory to Standard TreatmentJian Li